The SMBC provides accurate and absolute quantitation of small molecules in biological samples. Our services include UPLC-MS/MS assay development and validation, and sample analysis with or without sample processing. Current methods available from the core are listed below.
- Arachidonic Acid Panel
-
A method for selected metabolites of arachidonic acid in the cyclooxygenase pathways has been preliminarily developed:
- Prostaglandin A2 (PGA2)
- Prostaglandin D2 (PGD2): 15-deoxy PGD2
- Prostaglandin E2 (PGE2, shown above)
- Prostaglandin F1alpha (PGF1alpha): 6-keto PGF1alpha
- Prostaglandin F2alpha (PGF2alpha): 11-beta PGF2alpha
- Prostaglandin J2 (PGJ2): 15-deoxy PGJ2, Delta-12 PGJ2
- 11-dehydro thromboxane B2
Typical sample volume: Rat brain cortical tissue; 0.5 mL human plasma
Typical Lower Limit of Quantitation (LLOQ): 0.1-0.2 ng/mL in rat brain cortical tissue; 0.4 ng/mL in human plasma - Asymmetric Dimethylarginine (ADMA)
-
Method validated for asymmetric dimethylarginine (ADMA, shown below):
Typical sample volume: 0.2 mL cerebrospinal fluid (CSF); 0.1 mL serum
Typical Lower Limit of Quantitation (LLOQ): 1 ng/mL in CSF - Endocrine Panels
-
Methods validated for selected compounds in three endocrine panels:
Estrogens:
- Estradiol (shown above) LLOQ 1 pg/mL
- Estrone LLOQ 1 pg/mL
- Ethinylestradiol LLOQ 2.5 pg/mL
Typical sample volume: 0.5 mL serum/plasma
Typical Lower Limit of Quantitation (LLOQ): 1-2.5 pg/mL as shown above
Androgens:- Testosterone
- Androstenedione
Typical sample volume: 0.5 mL serum/plasma
Typical Lower Limit of Quantitation (LLOQ): 25 pg/mLProgestins:
- Etonogestrel
- Levonorgestrel
- Medroxyprogesterone acetate
- Norethindrone
- Progesterone
Typical sample volume: 0.5 mL serum/plasma
Typical Lower Limit of Quantitation (LLOQ): 25 pg/mL - Fexofenadine and Olmesartan
-
Method validated for fexofenadine and olmesartan (shown below):
Typical sample volume: 50 μL human serum
Typical Lower Limit of Quantitation (LLOQ): 1 ng/mL - Glyburide
-
Method validated for glyburide (shown below):
Typical sample volume: 200 μL serum; 400 μL brain tissue
Typical Lower Limit of Quantitation (LLOQ): 50 pg/mL - 20-HETE
-
Method validated for 20-hydroxyeicosatetraenoic acid (20-HETE, shown below):
Typical sample volume: 1.0 mL human cerebrospinal fluid (CSF); 0.5 mL human plasma
Typical Lower Limit of Quantitation (LLOQ): 0.2 ng/mL in human CSF; 0.4 ng/mL in human plasma - Ketamine Panel
-
Method validated for ketamine (shown below) and its metabolites including norketamine , dehydronorketamine, 2S,6S hydroxynorketamine, and 2R,6R hydroxynorketamine:
Typical sample volume: 200 μL serum
Typical Lower Limit of Quantitation (LLOQ): 0.1 ng/mL - LY2886721
-
Method validated for LY2886721 (shown below):
Typical sample volume: 25 μL serum or brain tissue
Typical Lower Limit of Quantitation (LLOQ): 0.5 ng/mL - Melatonin and N-Acetylserotonin
-
A method for melatonin and N-acetylserotonin (shown below) has been preliminarily developed:
Typical sample volume: 500 μL serum
Typical Lower Limit of Quantitation (LLOQ): 1 ng/mL - Methylnicotinamide (MNA)
-
Method validated for 1-methylnicotinamide (MNA, shown below), a methylated amide of nicotinic acid in human serum or urine:
Typical sample volume: 50 μL serum or urine
Typical Lower Limit of Quantitation (LLOQ): 1 ng/mL for serum; 0.5 μg/mL for urine - N6-Methyladenosine (m6A)
-
Method validated for N6-methyladenosine (m6A, shown below):
Typical sample volume: 50 μL cell lysate
Typical Lower Limit of Quantitation (LLOQ): 0.1 ng/mL - N-Acetylaspartate
-
Method validated for N-acetylaspartate (shown below):
Typical sample volume: 20 μL cerebrospinal fluid (CSF)
Typical Lower Limit of quantitation (LLOQ): 0.5 μM - Nucleoside Panel
-
A method for adenosine 3',5'-cyclic monophosphate (cAMP, shown below) and other metabolites has been preliminarily developed:
Typical sample volume: 100 μL cell lysates, urine or tissue
Typical Lower Limit of Quantitation (LLOQ): 0.05 ng/mL - Rivaroxaban and Apixaban
-
Method validated for rivaroxaban and apixaban (shown below):
Typical sample volume: 100 μL serum
Typical Lower Limit of Quantitation (LLOQ): 1 ng/mL - Sedative Panel
-
Method validated for a panel of nine sedatives and metabolites:
- Midazolam (MDZ) (shown above), morphine (MOR) and hydromorphone (HM) LLOQ 0.5 ng/mL
- Alpha hydroxymidazolam (1- OH MDZ) (shown above), morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) LLOQ 5 ng/mL
- Dexmedetomidine (DEX), fentanyl (FEN) and norfentanyl (NF) LLOQ 0.05 ng/mL
Typical sample volume: 100 μL human plasma
Typical Lower Limit of Quantitation (LLOQ): 0.05-5 ng/mL as shown above - Sildenafil
-
Method validated for sildenafil and N-desmehyl sildenafil (shown below):
Typical sample volume: 50 μL serum, tissue, or amniotic fluid
Typical Lower Limit of Quantitation (LLOQ): 0.5 ng/mL - TMAO Panel
-
Method validated for three metabolites of dietary phosphatidylcholine:
- Trimethylamine N-oxide (TMAO, shown above)
- Choline
- Betaine
Typical sample volume: 50 μL human plasma or urine
Typical Lower Limit of Quantitation (LLOQ): 10 ng/mL in plasma; 1000 ng/mL in urine - Uremic Toxin Panel
-
Method validated for four gut-derived uremic toxins:
- Kynurenic acid LLOQ 10 ng/mL
- Hippuric acid LLOQ 200 ng/mL
- Indoxyl sulfate (shown above) LLOQ 200 ng/mL
- p-Cresol sulfate LLOQ 250 ng/mL
Typical sample volume: 50 μL human serum
Typical Lower Limit of Quantitation (LLOQ): 10-250 ng/mL as shown above - Vitamin D Metabolite Panel
-
Method validated for 25-hydroxy vitamin D2, 25-hydroxy vitamin D3 (shown below) and selected metabolites:
Typical sample volume: 500 μL serum
Typical Lower Limit of Quantitation (LLOQ): 1 ng/mL - Warfarin and Metabolites
-
Method validated for R- and S-warfarin (shown below), warfarin and its metabolites:
R- and S-warfarin
Typical sample volume: 0.5 mL human urine
Typical Lower Limit of Quantitation (LLOQ): 5 ng/mLWarfarin and Alcohol Metabolites
Typical sample volume: 0.1 mL 10mM Tris-HCl incubation buffer
Typical Lower Limit of Quantitation (LLOQ): Warfarin 100 ng/mL; Warfarin Alcohols: 0.5 ng/mL
New UPLC-MS/MS assays are constantly being developed and validated. Please contact Dr. Raymond E. West III for more information.